GSK-BEL112626

Study Sponsor: GSK

Study Title

A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) who Completed the Phase 2 Protocol LBSL02

Medicine or Vaccine (generic name)

belimumab

Sponsor Identification Number

BEL112626

Trial Registry Identification Number(#'s)

NCT00583362

Medical Condition

Systemic Lupus Erythematosus

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=112626

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00583362

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

April 2019